However, persistent anemia remains a significant clinical challenge in a subset of patients treated with C5 inhibitors, primarily due to EVH, a phenomenon driven by C3 fragment deposition on RBCs and their subsequent removal by the mononuclear phagocyte system [25]. This evidence concerns the gene C5 and anemia (phenotype).